Publication

Video

Supplements and Featured Publications

Evolving Approaches to ALL Treatment: CAR T-cell Therapy
Volume1
Issue 1

Dr. Roddie on the Potential Utilization of Obe-Cel in R/R ALL

Claire Roddie, MD, discusses the potential utilization of obecabtagene autoleucel in relapsed/refractory acute lymphoblastic leukemia.

Claire Roddie, MD, hematologist, the University College London Hospital, London, UK, discusses the potential utilization of obecabtagene autoleucel (obe-cel; previously referred to as AUTO1) in relapsed/refractory acute lymphoblastic leukemia (ALL).

When utilizing CAR T-cell therapies, T-cells could signal to the point of not being functional in the patient, Roddie explains. However, obe-cel, a second-generation CD19 CAR T-cell agent, features a different binding kinetic than previous agents used in this space, Roddie explains. Because obe-cel quickly releases from CD19, CAR T-cells secrete less cytokine, which helps reduced the risk of immune toxicities typically seen from these agents, Roddie adds.

Furthermore, the quick release from the CD19 antigen allows obe-cel to have lower exposure to the leukemia target cells, Roddie continues. This allows the CAR T cells to last for longer periods of time within patients, Roddie explains. Overall, those are the potential biological benefits in the design of obe-cel, Roddie concludes.

Related Videos
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma